on April 15, 2017.
INTRODUCTION
Receptor tyrosine kinases (RTKs) are an extended family of cell surface proteins (1) that bind growth factors and hormones and play important roles in cell survival, growth, migration and differentiation (2) . In neoplastic/cancerous tissues, RTK overexpression, mutation and/or constitutive activation may result in uncontrolled proliferation and increased malignant phenotype (3).
EphA2 is an RTK that facilitates intercellular interactions via binding to its ligands ephrin-A1, -A3, -A4 and -A5 expressed on a proximal, opposing cell surface (3) . EphA2 is expressed primarily in cells of epithelial origin in a broad range of adult tissues including lung, spleen and kidney. In addition, EphA2 is expressed by activated endothelial cells and is associated with tissue neovascularization in adults (4) (5) (6) . Numerous studies have described EphA2 overexpression in a variety of tumors including melanoma, renal cell carcinoma and colon carcinoma, where the degree of overexpression of this RTK has been linked to poor prognosis and increased metastatic potential (7) (8) (9) . As a consequence, EphA2 has become an attractive target for therapeutic intervention in patients with solid tumors (10) .
Currently, there are several EphA2-centric therapeutic strategies contemplated for translation into clinical trials, including antibody-based strategies that antagonize the binding of EphA2 to its ligands or which block EphA2-mediated signal transduction (11) (12) (13) (14) (15) . Such approaches would inherently negate intrinsic EphA2-associated pro-tumor effects and provide a degree of (at least transient) therapeutic efficacy that is independent of the host immune system. However, since EphA2 protein levels are stabilized in tumor cells by HSP90 (16, 17) , a more therapeutically desirable situation would occur if one were to drive EphA2 degradation via the proteasome, enhancing the 
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Isolation of tumor, tumor-draining lymph node (TDLN), and spleen cells. Single-cell suspensions were obtained from mechanically-disrupted spleen and TDLN, and from enzymatically-digested tumors, as previously described (21).
Western blot. MCA205 cell lines were grown to 80-90% confluence and then incubated with 17-DMAG (10-1,000 nmol/L) in CM for 24-48 h. To assess the impact of proteasome function and endosomal acidification on EphA2 protein degradation promoted by 17-DMAG, MG-132 (50 μmol/L; Peptides International, Louisville, KY) and chloroquine (50 μmol/L; Sigma-Aldrich), respectively, were added to cells for 3h. After washing in PBS, cells were cultured in the presence of 17-DMAG (500 nM) for an additional 24h.
Harvested cells were then incubated with lysis buffer, and cell-free lysates were resolved by SDS-PAGE prior to electro-transfer onto polyvinylidene difluoride membranes as previously described (17), prior to probing with polyclonal anti-EphA2 antibody and horseradish peroxidase-conjugated goat anti-rabbit antibody reagents (both from Santa Cruz Biotechnology, San Diego, CA). Probed proteins were visualized by the Western Lighting chemiluminescence detection kit (Perkin-Elmer, Waltham, MA) and exposed to X-Omat film (Eastman Kodak, Rochester, NY) for 5-7 min.
Immunization of EphA2 -/-mice to generate EphA2-specific CD8 + T effector cells.
EphA2 -/-mice that are not tolerant to "self" EphA2 protein were vaccinated with 
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Auburn, CA) were analyzed for specific reactivity using CD107 cytotoxicity and IFN- ELISA assays. antibody images were taken using the same level of exposure on the channel settings.
Metamorph (Molecular Devices, Sunnyvale, CA) software was used for cell quantification. 
RESULTS

17-DMAG affects tumor RTK expression and viability in a dose-dependant manner.
17-DMAG is an HSP90 inhibitor currently being evaluated in phase I/II clinical trials (25-29). In preliminary in vitro studies, we determined that treatment of tumor cells with 17-DMAG resulted in their loss of EphA2 protein expression, with a clear drug dosedependency (Fig. 1A) . Expression of alternate tumor RTKs and known HSP90 client proteins, such as erbB2/Her2 and VEGFR2 (16, 17, 30) , and p53 (31), was also inhibited by 17-DMAG treatment in a dose-dependent manner (data not shown). 17-DMAGinduced loss of EphA2 protein expression in MCA205 sarcoma cells was dependant on the proteolytic activity of the proteasome and was not related to the enzymatic action of endosomes/lysosomes. Hence, addition of the proteasomal inhibitor MG132 to cultures prevented tumor cell EphA2 degradation induced by 17-DMAG treatment, while addition of the lysosomal inhibitor chloroquine (CLQ) to cultures had no discernable effect on 17-DMAG-associated EphA2 degradation (Fig 1B) . Treatment of MCA205 cell cultures with 17-DMAG did not modulate the expression of MHC class I molecules on the tumor cell surface (Fig 1C) or tumor cell viability/apoptotic frequency (data not shown). Notably, EphA2-specific CD8 + T cells developed from EphA2 -/-mice (Fig. S1 ) demonstrated increased in vitro recognition of EphA2 + MCA205 (but not EphA2 neg B16) tumor cells pretreated with 17-DMAG ( Fig. 1D and S1 ). Interestingly, in vivo-treated tumor cells were better recognized by anti-EphA2 CD8 + T cells, particularly after 5 days of treatment with 15 mg/kg of 17-DMAG, based on both the CD107 translocation and IFN- production assays ( Fig. 2C and 2D) . Notably, treatment of animals for more than 5 consecutive days with 17-DMAG resulted in the gradual erosion of this optimal day 5 Type-1 immunophenotype in the TME. Based on these results, all subsequent experiments used a standard 17-DMAG treatment regimen (i.e. 15 mg/kg provided orally for 5 days).
17-DMAG promotes sarcoma regression in association with
The beneficial effects of 17-DMAG administration persist even after discontinuation of therapy on day 5. To evaluate the durability of 17-DMAG-associated immunomodulation in vivo, MCA205 tumor-bearing mice were treated with 15 mg/kg of 17-DMAG for 5 days and then followed for up to 28 days. As shown in Fig. 3A , treatment with 17-DMAG promoted tumor regression through day 10 (5 days after drug discontinuation), after which time slow tumor growth was observed through day 28.
Tumor expression of EphA2 protein in vivo was precipitously reduced during the drug treatment window and only began to return to control levels 10-15 days after the discontinuation of drug (Fig. 3B) . 12 vivo treated tumor cells remained significantly elevated through day 10-14 after treatment initiation (Fig. 3C) and the predominance of CD4 + and CD8 + T effector cells (and CD11c + DC) over regulatory (MDSC and Treg) cells within the treated TME persisted through day 28 in these experiments (Fig. 3D) . We also observed that 17-DMAG treated tumors displayed a prolonged, increase in expression of both VCAM-1 and the CXCR3 ligand chemokine CXCL10 in situ, even after discontinuation of this monotherapy (Fig. S2) .
Furthermore, TUNEL staining of tumor sections demonstrated increased frequencies of apoptotic cell death within the TME of 17-DMAG-treated versus untreated MCA205
lesions at all time points through day 28 (Fig. S2) . (Fig. 4A ). An analysis of TIL harvested from the various treatment groups supports the superior and analyzed the ability of these target cells to be recognized by anti-EphA2 CD8 + T cells developed from EphA2 -/-mice (Fig. 5C) or by CD8 + TIL isolated from mice treated with the superior combined therapy (i.e. DC/EphA2 peptide vaccine + 17-DMAG) 6 days after the initiation of treatment (Fig. 5D) . We observed that anti-EphA2 Tc1 populations preferentially recognized tumor-associated VEC isolated from DMAG (+/-vaccine)-treated mice in an MHC class I-restricted manner (Fig. 5C ), but these T cells failed to Rao et al. 14 recognize tumor-uninvolved kidney-associated VEC or cultured B16 tumor cells (Fig. 5C,   5D ). injection. EphA2-specific CD8 + T cells were isolated from the spleens of EphA2 -/-mice previously vaccinated with syngenic DC pulsed with EphA2 peptides (Fig. S1 ). Splenic CD8 + T cells from EphA2 -/-mice vaccinated with syngenic DC alone (no peptide) served as controls. The optimum time-point for injection of the therapeutic Type-1 EphA2-specific T cells (i.e. day 4) was determined empirically by performing adoptive transfers at various time-points after initiating 17-DMAG treatment (Fig. S3) . We observed that adoptive transfer of EphA2-specific T cells 4 days after initiating a 5 day course of 17-DMAG (15 mg/kg/day) yielded superior anti-tumor protection when compared to all other treatment cohorts ( Fig. 6A) , in concert with improved levels of CD4eff and CD8 + TIL and reduced levels of tumor-associated regulatory cell populations (Fig. 6B) , and the accumulation of anti-EphA2 + Tc1 in the MCA205 TME (Fig. 6C) . We also noted that tumor core necrosis and ulceration occurred uniquely in animals treated with the combination of EphA2-immune T cells + 17-DMAG (necessitating the euthanasia of these regressing mice per the guidelines of our IACUC-approved protocol). 
Combination vaccination
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DISCUSSION
The major finding in this report is that the HSP90 inhibitor 17-DMAG functions as an immune adjuvant in the context of vaccines targeting the HSP90 client protein, EphA2. It appears to perform this function in at least 3 ways, by: i.) reducing suppressor cell populations such as MDSC and Treg within the TME, ii.) activating the tumor-associated vasculature and promoting locoregional production of chemokines (such as CXCL10) that recruit protective, Type-1 T effector cells, and iii.) enhancing the (proteasome-dependent) processing of tumor EphA2 protein and subsequent recognition of these tumor (and tumor-associated VEC) by anti-EphA2 CD8 + T cells elicited by specific vaccination or provided via adoptive transfer. These therapeutically beneficial effects of orally administered 17-DMAG occurred rapidly, were maximal by day 5 of drug provision, and were sustained for a prolonged period of 1-3 weeks (depending on the specific index), as long as treatment with the HSP90 inhibitor was discontinued after a 5 day course.
Prolonged application of 17-DMAG for > 5 days appeared to result in the erosion of its potent adjuvant-like qualities by as early as day 7 in chronic treatment protocols. Why such immunologic silencing occurs upon extended 17-DMAG administration is currently unclear. However, previous studies have suggested the potential attenuating effects of high-dose, long-term dosing of 17-DMAG on the immune system (7, 35, 36) . We plan to intensively investigate the mechanism(s) underlying the deleterious effects of more "chronic" 17-DMAG administration in future studies.
The capacity of this combination immunotherapy to target both EphA2 + tumor cells and/or VEC in the TME has important translational ramifications since EphA2 Importantly, 17-DMAG administration combined with either active vaccination to induce anti-EphA2 Tc1 in vivo (Fig. 4A, 5A ) or the adoptive transfer of anti-EphA2 CD8 + T cells (Fig. 6A) 
Rao et al. 17
objective clinical responses (including 1 complete response) based on RECIST criteria were reported in a minority of patients with kidney or prostate carcinoma, melanoma or chondrosarcoma (26). Like many chemotherapeutic agents, HSP90 inhibitors fail to exert durable anti-cancer efficacy based on intrinsic disease resistance or the development of acquired resistance among treated populations of cancer cells (43) (44) (45) . In the case of 17-DMAG, such acquired resistance could be due to the ability of this agent to upregulate expression of the cytoprotective HSP70 and/or Bcl-2 molecules (46, 47) . Such clinical limitations reinforce the need to evolve more effective combinational therapeutic strategies.
Our data suggest that sustained therapeutic benefits can be obtained by combining a 
